Treats uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae…. ANDA 40274, held by Aurobindo Pharma USA. Hydroxychloroquine Sulfate.
As of Nov 15, 2026, ANDA 40274 (Hydroxychloroquine Sulfate), held by Aurobindo Pharma USA, was first approved by FDA on May 29, 1998, with 7 approved supplements and 0 published complete response letters.
Hydroxychloroquine sulfate tablets are an antimalarial and antirheumatic indicated for the: Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients. Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients. Treatment of rheumatoid arthritis in adults. Treatment of systemic lupus erythematosus in adults. Treatment of chronic discoid lupus erythematosus in adults. Limitations of Use: Hydroxychloroquine sulfate tablets are not recommended for the: Treatment of complicated malaria.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 29, 1998 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydroxychloroquine Sulfate200MG · tablet;oral | Hydroxychloroquine Sulfate | Rx |
| Oct 11, 2024 | Supplement 24Labeling · Standard review | Approved | None posted |
| Jul 11, 2022 | Supplement 20Labeling · Standard review | Approved | None posted |
| Aug 23, 2021 | Supplement 18Labeling · Standard review | Approved | None posted |
| Apr 9, 2020 | Supplement 15Labeling · Standard review | Approved | None posted |
| Apr 1, 2020 | Supplement 13Labeling · Standard review | Approved | |
| Jan 20, 2015 | Supplement 10Labeling · Standard review | Approved | None posted |
| Sep 10, 2002 | Supplement 1Labeling | Approved | None posted |
| May 29, 1998 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters